Johnson & Johnson EBITDA Margin 2010-2024 | JNJ
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Johnson & Johnson (JNJ) over the last 10 years. The current EBITDA margin for Johnson & Johnson as of March 31, 2024 is .
| Johnson & Johnson EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2023-12-31 |
$85.16B |
$24.58B |
28.86% |
| 2023-09-30 |
$84.18B |
$23.30B |
27.69% |
| 2023-06-30 |
$82.82B |
$22.75B |
27.47% |
| 2023-03-31 |
$81.31B |
$21.03B |
25.86% |
| 2022-12-31 |
$79.99B |
$27.10B |
33.87% |
| 2022-09-30 |
$77.21B |
$25.56B |
33.11% |
| 2022-06-30 |
$80.55B |
$24.20B |
30.04% |
| 2022-03-31 |
$79.85B |
$25.07B |
31.39% |
| 2021-12-31 |
$78.74B |
$26.80B |
34.04% |
| 2021-09-30 |
$91.45B |
$27.34B |
29.89% |
| 2021-06-30 |
$89.19B |
$27.92B |
31.30% |
| 2021-03-31 |
$84.21B |
$25.09B |
29.80% |
| 2020-12-31 |
$82.58B |
$24.04B |
29.11% |
| 2020-09-30 |
$80.86B |
$26.55B |
32.84% |
| 2020-06-30 |
$80.50B |
$23.79B |
29.55% |
| 2020-03-31 |
$82.73B |
$26.98B |
32.61% |
| 2019-12-31 |
$82.06B |
$25.01B |
30.48% |
| 2019-09-30 |
$81.71B |
$24.12B |
29.51% |
| 2019-06-30 |
$81.33B |
$27.18B |
33.42% |
| 2019-03-31 |
$81.59B |
$25.33B |
31.04% |
| 2018-12-31 |
$81.58B |
$26.54B |
32.54% |
| 2018-09-30 |
$81.38B |
$26.03B |
31.98% |
| 2018-06-30 |
$80.68B |
$26.26B |
32.55% |
| 2018-03-31 |
$78.69B |
$25.42B |
32.31% |
| 2017-12-31 |
$76.45B |
$24.63B |
32.22% |
| 2017-09-30 |
$74.36B |
$25.51B |
34.30% |
| 2017-06-30 |
$72.53B |
$25.18B |
34.72% |
| 2017-03-31 |
$72.17B |
$25.04B |
34.69% |
| 2016-12-31 |
$71.89B |
$24.65B |
34.29% |
| 2016-09-30 |
$71.60B |
$23.99B |
33.51% |
| 2016-06-30 |
$70.88B |
$22.72B |
32.06% |
| 2016-03-31 |
$70.18B |
$23.42B |
33.37% |
| 2015-12-31 |
$70.07B |
$23.62B |
33.71% |
| 2015-09-30 |
$70.52B |
$22.47B |
31.86% |
| 2015-06-30 |
$71.88B |
$25.16B |
35.00% |
| 2015-03-31 |
$73.59B |
$25.09B |
34.10% |
| 2014-12-31 |
$74.33B |
$25.06B |
33.71% |
| 2014-09-30 |
$74.43B |
$25.21B |
33.87% |
| 2014-06-30 |
$73.54B |
$22.08B |
30.03% |
| 2014-03-31 |
$71.92B |
$21.28B |
29.59% |
| 2013-12-31 |
$71.31B |
$20.13B |
28.23% |
| 2013-09-30 |
$70.52B |
$20.39B |
28.91% |
| 2013-06-30 |
$69.99B |
$20.37B |
29.11% |
| 2013-03-31 |
$68.59B |
$17.50B |
25.51% |
| 2012-12-31 |
$67.22B |
$18.04B |
26.83% |
| 2012-09-30 |
$65.92B |
$15.16B |
22.99% |
| 2012-06-30 |
$64.87B |
$15.45B |
23.82% |
| 2012-03-31 |
$65.00B |
$16.75B |
25.77% |
| 2011-12-31 |
$65.03B |
$16.18B |
24.88% |
| 2011-09-30 |
$64.42B |
$17.96B |
27.88% |
| 2011-06-30 |
$63.40B |
$17.98B |
28.36% |
| 2011-03-31 |
$62.13B |
$18.71B |
30.11% |
| 2010-12-31 |
$61.59B |
$20.45B |
33.20% |
| 2010-09-30 |
$62.49B |
$20.74B |
33.19% |
| 2010-06-30 |
$62.59B |
$20.77B |
33.18% |
| 2010-03-31 |
$62.50B |
$20.77B |
33.23% |
| 2009-12-31 |
$61.90B |
$19.07B |
30.81% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$359.347B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
